- Cytiva and Pear Bio collaborate to improve cancer research and personalized treatment through advanced tumor cell analysis.
- Pear Bio leverages Cytiva’s Via Extractor technology to ensure high cell viability for more accurate and efficient cancer drug testing.
Cytiva, a global life sciences company, has announced a collaboration with Pear Bio, a company pioneering personalized cancer treatments. This partnership aims to advance cancer research by improving tumor cell analysis through the use of Cytiva’s Via Extractor technology. The technology enables Pear Bio to produce dissociated tumor cell suspensions with high viability, which is critical for accurate cancer treatment testing.
Pear Bio uses this technology to process tumor cells and matched immune cells from cancer patients, culturing them ex vivo in 3D environments. The company tests the efficacy of FDA-approved therapies specific to various cancers, relying on the high cell viability provided by Cytiva’s Via Extractor for their downstream workflow. The quality of the tumor cells directly impacts the precision of the analysis, which is conducted over a five-day period using 3D imaging and data analysis.
“This advancement is a significant step forward in the fight against cancer,” said Tim Bervoets, President of Discovery & Medical at Cytiva. He emphasised how Cytiva’s technology is helping to improve cancer treatment research and ultimately patient outcomes.
John Curran, Chief Operating Officer and Laboratory Director at Pear Bio, praised the Via Extractor’s performance, noting its role in enabling more reliable and efficient results in their cancer medicine analysis.
Pear Bio has integrated Cytiva’s Via Extractor into their workflows across both UK and US laboratories, ensuring high levels of cell viability and consistency in their testing process.
Overview of outsourcing trends 
